Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251774 | 0.88 | DGAT1 (0.65) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL18229629 | 0.86 | HDAC6 (1.00) | HDAC3HDAC7HDAC6HDAC9DGAT1 | |
| SCHEMBL1252016 | 0.86 | HDAC3 (0.74) | HDAC3HDAC7HDAC6HDAC9CHEK2 | |
| SCHEMBL3167982 | 0.86 | DGAT1 (0.68) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL3162874 | 0.85 | HDAC3 (0.56) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL3178974 | 0.84 | DGAT1 (0.58) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL3182465 | 0.81 | HDAC3 (0.52) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL27786026 | 0.80 | HSP90AA1 (0.53) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL3162726 | 0.80 | DGAT1 (0.61) | HDAC3HDAC7HDAC6HDAC9HSP90AA1 | |
| SCHEMBL1250492 | 0.80 | DGAT1 (0.82) | HDAC3HDAC7HDAC6HDAC9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20100016387-A1 | METHOD OF TREATMENT | BOSE AVIRUP | 2010-01-21 | — | — | US | disclosed |
| CN-101600437-A | method for preventing or treating myocardial ischemia | NOVARTIS AG (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016387-A1 | METHOD OF TREATMENT | DGAT1, DGAT2, DGKA | HDAC3 176/4885HDAC7 666/4885HDAC6 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.